Please ensure Javascript is enabled for purposes of website accessibility

From the 2nd of July 2024 we will be changing the way our service is accessed for more information click here

Thank you for your understanding and patience whilst we implement this!

We Are Open

There is a worldwide shortage of injectable and oral GLP-1 analogue receptor agonist (GLP-1s) medicines for type 2 diabetes. These include Dulaglutide (Trulicity®), Exenatide (Byetta® or Bydureon®), Semaglutide (Ozempic® or Rybelsus®), Liraglutide (Victoza®) and Lixisenatide (Lyxumia®).

Due to increased global use, manufacturers are currently unable to produce enough of these diabetic injectable medicines to meet demand. Supply is not expected to return to normal until at least the middle of 2024.

All patients using GLP-1 analogues will be contacted over the coming weeks to arrange a medication review, and a blood test if required. It is important to attend the practice or hospital when you receive this request.

Please remember that GLP-1 RAs should only be obtained on prescription from registered pharmacies.  It is illegal to obtain GLP-1 RA without a prescription and there is a risk that the medicine may not be genuine.

If you feel unwell with symptoms of high blood glucose, please seek medical help as normal.

We are working through the list of our patients affected and contacting them with advice regarding possible alternatives. For general queries about this or how long the shortage will last, please remember this is beyond our control and we are dealing with a high volume of calls. Please be assured we will be in touch.

Please see link below for more information